Genetic Technologies Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GNTLF research report →
Companywww.gtglabs.com
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons.
- CEO
- Kevin Camilleri
- IPO
- 2000
- Employees
- 55
- HQ
- Fitzroy, VIC, AU
Price Chart
Valuation
- Market Cap
- $1.34B
- P/E
- -0.45
- P/S
- 0.74
- P/B
- 2.95
- EV/EBITDA
- -0.48
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 50.94%
- Op Margin
- -159.30%
- Net Margin
- -156.78%
- ROE
- -184.98%
- ROIC
- -429.43%
Growth & Income
- Revenue
- $9.67M · -6.52%
- Net Income
- $-12,017,219 · -2.27%
- EPS
- $-0.09 · 24.25%
- Op Income
- $-12,210,212
- FCF YoY
- 0.29%
Performance & Tape
- 52W High
- $1.00
- 52W Low
- $1.00
- 50D MA
- $1.00
- 200D MA
- $1.00
- Beta
- 0.18
- Avg Volume
- 61.2
Get TickerSpark's AI analysis on GNTLF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our GNTLF Coverage
We haven't published any research on GNTLF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GNTLF Report →